Urogen Pharma Ltd (NASDAQ:URGN) CFO Peter P. Pfreundschuh Sells 1,416 Shares

Urogen Pharma Ltd (NASDAQ:URGN) CFO Peter P. Pfreundschuh sold 1,416 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.07, for a total transaction of $46,827.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of URGN traded down $0.07 during mid-day trading on Friday, reaching $31.62. The company had a trading volume of 3,798 shares, compared to its average volume of 175,268. The company’s 50 day simple moving average is $32.84 and its 200 day simple moving average is $36.40. Urogen Pharma Ltd has a 1-year low of $30.48 and a 1-year high of $55.49. The company has a market capitalization of $445.96 million, a price-to-earnings ratio of -6.59 and a beta of 1.21.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Friday, August 9th. The company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.12. The business had revenue of $0.02 million for the quarter. On average, analysts anticipate that Urogen Pharma Ltd will post -4.95 earnings per share for the current year.

A number of research firms have recently weighed in on URGN. Goldman Sachs Group began coverage on shares of Urogen Pharma in a research note on Wednesday, May 29th. They issued a “neutral” rating and a $50.00 price target on the stock. Cowen restated a “buy” rating on shares of Urogen Pharma in a research note on Monday, May 6th. ValuEngine upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Finally, HC Wainwright set a $75.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research note on Tuesday, May 28th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $59.00.

Large investors have recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado bought a new stake in shares of Urogen Pharma in the 1st quarter valued at $41,000. Bank of Montreal Can bought a new stake in shares of Urogen Pharma in the 2nd quarter valued at $56,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Urogen Pharma by 112.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after acquiring an additional 1,282 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Urogen Pharma by 50.0% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,000 shares of the company’s stock valued at $108,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of Urogen Pharma in the 2nd quarter valued at $179,000.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Story: What is an overbought condition?

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.